{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T23:04:17Z","timestamp":1783897457781,"version":"3.55.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Rep."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Metastatic castration-resistant prostate cancer (mCRPC) is bone-predominant, requiring objective imaging biomarkers to guide Ra-223 therapy. We evaluated overall metabolic bone volume (OMBV) and overall total bone uptake (OTBU) from bone SPECT\/CT as prognostic markers in mCRPC patients treated with Ra-223.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Thirty mCRPC patients underwent pre-treatment planar and SPECT\/CT bone scintigraphy, with OMBV and OTBU derived using GI-BONE software. Overall survival (OS) was the primary endpoint; progression-free survival (PFS) and time to symptomatic skeletal event (TTSE) were secondary. Receiver operating characteristic analysis (Youden index) defined cut-offs for OS and TTSE independently. Treatment response was classified by composite changes in OMBV, OTBU, and bone scan index. OS, OMBV, and OTBU were analyzed by univariate Cox regression as continuous and dichotomized variables.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Baseline skeletal burden was substantial (median OMBV 1,191.21\u2009cm\n                      <jats:sup>3<\/jats:sup>\n                      [IQR 93.80\u20131,948.01]; median OTBU 9,746.18 [1,280.01\u2013 17,587.11]); 87% had extent of disease grade 3\u20134. Post-treatment imaging in 24 patients yielded 10 responders (42%) and 14 non-responders (58%), with responder mean OMBV and OTBU reductions of 57% and 68%. Dichotomized baseline OMBV (hazard ratio [HR] 6.0320, 95% confidence interval [CI] 1.6880\u201321.5546;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and OTBU (HR 9.4492, 95% CI 2.0968\u201342.5826;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) were significant predictors of OS. OMBV and OTBU were not significantly associated with PFS or TTSE.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>OMBV and OTBU from bone SPECT\/CT may provide useful prognostic information in mCRPC patients undergoing Ra-223 therapy, offering objective quantification of skeletal tumor burden using widely available technology. Further validation in larger cohorts is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41824-026-00309-4","type":"journal-article","created":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T22:09:12Z","timestamp":1783894152000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Quantitative bone SPECT\/CT-derived tumor burden as a prognostic biomarker in metastatic castration-resistant prostate cancer treated with Ra-223"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6224-4914","authenticated-orcid":false,"given":"Yoshimitsu","family":"Fukushima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Go","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Akatsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimitsu","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujiro","family":"Nakaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromitsu","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Kumita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"issue":"1","key":"309_CR1","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1158\/1078-0432.CCR-09-2514","volume":"16","author":"AJ Armstrong","year":"2010","unstructured":"Armstrong AJ, Garrett-Mayer E, de Wit R, Tannock I, Eisenberger M (2010) Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 16(1):203\u2013211. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-2514","journal-title":"Clin Cancer Res"},{"issue":"10","key":"309_CR2","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1007\/s00259-008-0841-y","volume":"35","author":"L Bodei","year":"2008","unstructured":"Bodei L, Lam M, Chiesa C, Flux G, Brans B, Chiti A, Giammarile F (2008) EANM procedure guideline for treatment of refractory metastatic bone pain. Eur J Nucl Med Mol Imag 35(10):1934\u20131940. https:\/\/doi.org\/10.1007\/s00259-008-0841-y","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"1","key":"309_CR3","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1093\/jnci\/dji002","volume":"97","author":"JE Brown","year":"2005","unstructured":"Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee K-A, Zheng M, Hei Y-J, Coleman RE (2005) Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. JNCI J The Natl Cancer Inst 97(1):59\u201369. https:\/\/doi.org\/10.1093\/jnci\/dji002","journal-title":"JNCI J The Natl Cancer Inst"},{"key":"309_CR4","doi-asserted-by":"publisher","unstructured":"Bruland OS, Nilsson S, Fisher DR, Larsen RH (2006) High-linear energy transfer irradiation targeted to skeletal metastases by the alpha emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res 12(20):6250s\u20136257s. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-0841","DOI":"10.1158\/1078-0432.CCR-06-0841"},{"issue":"5","key":"309_CR5","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1053\/hp.2000.6698","volume":"31","author":"L Bubendorf","year":"2000","unstructured":"Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ (2000) Metastatic patterns of prostate cancer: an autopsy study of 1, 589 patients. Hum Pathol 31(5):578\u2013583. https:\/\/doi.org\/10.1053\/hp.2000.6698","journal-title":"Hum Pathol"},{"issue":"6","key":"309_CR6","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40336-016-0196-5","volume":"4","author":"GJR Cook","year":"2016","unstructured":"Cook GJR, Azad G, Padhani AR (2016) Bone imaging in prostate cancer: the evolving roles of nuclear medicine and radiology. Clin Transl Imag 4(6):439\u2013447. https:\/\/doi.org\/10.1007\/s40336-016-0196-5","journal-title":"Clin Transl Imag"},{"issue":"11","key":"309_CR7","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1158\/1078-0432.CCR-06-0269","volume":"12","author":"RJ Cook","year":"2006","unstructured":"Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, Saad F, Smith MR (2006) Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res 12(11):3361\u20133367. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-0269","journal-title":"Clin Cancer Res"},{"issue":"21","key":"309_CR8","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"de Bono Js","year":"2011","unstructured":"de Bono Js, Logothetis CJ, Molina A, de Bono JS, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fl\u00e9chon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364(21):1995\u20132005. https:\/\/doi.org\/10.1056\/NEJMoa1014618","journal-title":"N Engl J Med"},{"issue":"5","key":"309_CR9","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1200\/JCO.2011.36.5791","volume":"30","author":"ER Dennis","year":"2012","unstructured":"Dennis ER, Jia X, Mezheritskiy IS, Stephenson RD, Schoder H, Fox JJ, Heller G, Scher HI, Larson SM, Morris MJ (2012) Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. JCO 30(5):519\u2013524. https:\/\/doi.org\/10.1200\/JCO.2011.36.5791","journal-title":"JCO"},{"issue":"1","key":"309_CR10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.2967\/jnumed.119.240408","volume":"62","author":"H Dittmann","year":"2021","unstructured":"Dittmann H, Kaltenbach S, Weissinger M, Fiz F, Martus P, Pritzkow M, Kupferschlaeger J, la Foug\u00e8re C (2021) The prognostic value of quantitative bone SPECT\/CT before 223 Ra treatment in metastatic castration-resistant prostate cancer. J Nucl Med 62(1):48\u201354. https:\/\/doi.org\/10.2967\/jnumed.119.240408","journal-title":"J Nucl Med"},{"issue":"8","key":"309_CR11","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.2967\/jnumed.115.158626","volume":"56","author":"EC Etchebehere","year":"2015","unstructured":"Etchebehere EC, Araujo JC, Fox PS, Swanston NM, Macapinlac HA, Rohren EM (2015) Prognostic factors in patients treated with 2 2 3 Ra: the role of skeletal tumor burden on baseline 18F-fluoride PET\/CT in predicting overall survival. J Nucl Med 56(8):1177\u20131184. https:\/\/doi.org\/10.2967\/jnumed.115.158626","journal-title":"J Nucl Med"},{"issue":"2","key":"309_CR12","first-page":"287","volume":"47","author":"E Even-Sapir","year":"2006","unstructured":"Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I (2006) The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET\/CT. J Nucl Med 47(2):287\u2013297","journal-title":"J Nucl Med"},{"issue":"9768","key":"309_CR13","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, Carducci M, Smith M, Dami\u00e3o R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377(9768):813\u2013822. https:\/\/doi.org\/10.1016\/S0140-6736(10)62344-6","journal-title":"Lancet"},{"issue":"1","key":"309_CR14","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.eururo.2014.10.001","volume":"68","author":"K Fizazi","year":"2015","unstructured":"Fizazi K, Massard C, Smith M, Rader M, Brown J, Milecki P, Shore N, Oudard S, Karsh L, Carducci M, Dami\u00e3o R, Wang H, Ying W, Goessl C (2015) Bone-related parameters are the main prognostic factors for overall survival in men with bone metastases from castration-resistant prostate cancer. Eur Urology 68(1):42\u201350. https:\/\/doi.org\/10.1016\/j.eururo.2014.10.001","journal-title":"Eur Urology"},{"issue":"7","key":"309_CR15","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1200\/JCO.2013.52.3696","volume":"32","author":"S Halabi","year":"2014","unstructured":"Halabi S, Lin CY, Kelly WK, Fizazi KS, Moul JW, Kaplan EB, Morris MJ, Small EJ (2014) Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. JCO 32(7):671\u2013677. https:\/\/doi.org\/10.1200\/JCO.2013.52.3696","journal-title":"JCO"},{"issue":"12","key":"309_CR16","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s12149-024-01967-9","volume":"38","author":"X Hou","year":"2024","unstructured":"Hou X, He Y, Liu G, Chen S, Shi H et al (2024) SPECT\/CT imaging: quantifying 99mTc-MDP concentration in the spine and pelvis. Ann Nucl Med 38(12):933\u2013942. https:\/\/doi.org\/10.1007\/s12149-024-01967-9","journal-title":"Ann Nucl Med"},{"issue":"7","key":"309_CR17","first-page":"1765","volume":"4","author":"M Imbriaco","year":"1998","unstructured":"Imbriaco M, Larson SM, Yeung HW, Mawlawi OR, Erdi Y, Venkatraman ES, Scher HI (1998) A new parameter for measuring metastatic bone involvement by prostate cancer: the bone scan index. Clin Cancer Res 4(7):1765\u20131772","journal-title":"Clin Cancer Res"},{"issue":"1","key":"309_CR18","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1159\/000475018","volume":"28","author":"T Jorgensen","year":"1995","unstructured":"Jorgensen T, Muller C, Kaalhus O, Danielsen HE, Tveter KJ (1995) Extent of disease based on initial bone scan: important prognostic predictor for patients with metastatic prostatic cancer. Eur Urol 28(1):40\u201346. https:\/\/doi.org\/10.1159\/000475018","journal-title":"Eur Urol"},{"issue":"1","key":"309_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/2191-219X-3-9","volume":"3","author":"R Kaboteh","year":"2013","unstructured":"Kaboteh R, Damber JE, Gjertsson P, H\u00f6glund P, Lomsky M, Ohlsson M, Edenbrandt L (2013) Bone scan index: a prognostic imaging biomarker for high-risk prostate cancer patients receiving primary hormonal therapy. EJNMMI Res 3(1):9. https:\/\/doi.org\/10.1186\/2191-219X-3-9","journal-title":"EJNMMI Res"},{"issue":"1","key":"309_CR20","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s41824-017-0006-y","volume":"1","author":"I Kuji","year":"2017","unstructured":"Kuji I, Yamane T, Seto A, Yasumizu Y, Shirotake S, Oyama M (2017) Skeletal standardized uptake values obtained by quantitative SPECT\/CT as an osteoblastic biomarker for the discrimination of active bone metastasis in prostate cancer. Eur J Hybrid Imag 1(1):2. https:\/\/doi.org\/10.1186\/s41824-017-0006-y","journal-title":"Eur J Hybrid Imag"},{"issue":"4","key":"309_CR21","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1023\/A:1006106209527","volume":"17","author":"PH Lange","year":"1998","unstructured":"Lange PH, Vessella RL (1998) Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone. Cancer Metastasis Rev 17(4):331\u2013336. https:\/\/doi.org\/10.1023\/A:1006106209527","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"309_CR22","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/nrc1528","volume":"5","author":"CJ Logothetis","year":"2005","unstructured":"Logothetis CJ, Lin SH (2005) Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 5(1):21\u201328. https:\/\/doi.org\/10.1038\/nrc1528","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"309_CR23","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12885-016-2176-6","volume":"16","author":"Y Miyoshi","year":"2016","unstructured":"Miyoshi Y, Yoneyama S, Kawahara T, Hattori Y, Teranishi J-I, Kondo K, Moriyama M, Takebayashi S, Yokomizo Y, Yao M, Uemura H, Noguchi K (2016) Prognostic value of the bone scan index using a computer-aided diagnosis system for bone scans in hormone-naive prostate cancer patients with bone metastases. BMC Cancer 16(1):128. https:\/\/doi.org\/10.1186\/s12885-016-2176-6","journal-title":"BMC Cancer"},{"issue":"5","key":"309_CR24","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s11604-021-01226-1","volume":"40","author":"K Moridera","year":"2022","unstructured":"Moridera K, Kitajima K, Yoshikawa K, Takaoka K, Tsuchitani T, Noguchi K, Kishimoto H, Yamakado K (2022) Usefulness of quantitative bone SPECT\/CT for medication-related osteonecrosis of the jaw in clinical settings. Jpn J Radiol 40(5):492\u2013499. https:\/\/doi.org\/10.1007\/s11604-021-01226-1","journal-title":"Jpn J Radiol"},{"issue":"11","key":"309_CR25","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1007\/s00259-017-3744-y","volume":"44","author":"I Murray","year":"2017","unstructured":"Murray I, Chittenden SJ, Denis-Bacelar AM, Hindorf C, Parker CC, Chua S, Flux GD (2017) The potential of 2 2 3 Ra and 1 8 F-fluoride imaging to predict bone lesion response to treatment with 2 2 3 Ra-dichloride in castration-resistant prostate cancer. Eur J Nucl Med Mol Imag 44(11):1832\u20131844. https:\/\/doi.org\/10.1007\/s00259-017-3744-y","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"3","key":"309_CR26","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D, Helle SI, O\u2019Sullivan JM, Foss\u00e5 SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall\u2019Oglio M, Franz\u00e9n L, Coleman R, Vogelzang NJ, O\u2019Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland OS, Sartor O (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369(3):213\u2013223. https:\/\/doi.org\/10.1056\/NEJMoa1213755","journal-title":"N Engl J Med"},{"issue":"4","key":"309_CR27","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s00520-014-2525-4","volume":"23","author":"DL Patrick","year":"2015","unstructured":"Patrick DL, Cleeland CS, von Moos R, Fallowfield L, Wei R, \u00d6hrling K, Qian Y (2015) Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agents. Support Care Cancer 23(4):1157\u20131168. https:\/\/doi.org\/10.1007\/s00520-014-2525-4","journal-title":"Support Care Cancer"},{"issue":"5","key":"309_CR28","doi-asserted-by":"publisher","first-page":"629","DOI":"10.31616\/asj.2019.0308","volume":"14","author":"MFM Rohani","year":"2020","unstructured":"Rohani MFM, Yonan SNM, Tagiling N, Zainon MSF, Udin Y, Nawi NM et al (2020) Standardized uptake value from semiquantitative bone single-photon emission computed tomography\/computed tomography in normal thoracic and lumbar vertebrae of breast cancer patients. Asian Spine J 14(5):629\u2013638. https:\/\/doi.org\/10.31616\/asj.2019.0308","journal-title":"Asian Spine J"},{"issue":"16","key":"309_CR29","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1056\/NEJMra030831","volume":"350","author":"GD Roodman","year":"2004","unstructured":"Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350(16):1655\u20131664. https:\/\/doi.org\/10.1056\/NEJMra030831","journal-title":"N Engl J Med"},{"issue":"2","key":"309_CR30","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PFA, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin M-E, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368(2):138\u2013148. https:\/\/doi.org\/10.1056\/NEJMoa1209096","journal-title":"N Engl J Med"},{"issue":"1","key":"309_CR31","first-page":"53","volume":"45","author":"LD Rybak","year":"2001","unstructured":"Rybak LD, Rosenthal DI (2001) Radiological imaging for the diagnosis of bone metastases. Q J Nucl Med 45(1):53\u201364","journal-title":"Q J Nucl Med"},{"issue":"6","key":"309_CR32","doi-asserted-by":"publisher","first-page":"390","DOI":"10.3816\/CGC.2007.n.022","volume":"5","author":"F Saad","year":"2007","unstructured":"Saad F, Chen YM, Gleason DM, Chin J (2007) Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases. Clin Genitourin Cancer 5(6):390\u2013396. https:\/\/doi.org\/10.3816\/CGC.2007.n.022","journal-title":"Clin Genitourin Cancer"},{"issue":"11","key":"309_CR33","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1093\/jnci\/djh141","volume":"96","author":"F Saad","year":"2004","unstructured":"Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Zheng M (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. JNCI J The Natl Cancer Inst 96(11):879\u2013882. https:\/\/doi.org\/10.1093\/jnci\/djh141","journal-title":"JNCI J The Natl Cancer Inst"},{"issue":"8","key":"309_CR34","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1002\/cncr.22991","volume":"110","author":"F Saad","year":"2007","unstructured":"Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R (2007) Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 110(8):1860\u20131867. https:\/\/doi.org\/10.1002\/cncr.22991","journal-title":"Cancer"},{"issue":"12","key":"309_CR35","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, Park CH, Beer TM, Armour A, P\u00e9rez-Contreras WJ, DeSilvio M, Kpamegan E, Gericke G, Messmann RA, Morris MJ, Krause BJ (2021) Lutetium-177\u2013PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med 385(12):1091\u20131103. https:\/\/doi.org\/10.1056\/NEJMoa2107322","journal-title":"N Engl J Med"},{"issue":"13","key":"309_CR36","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin M-E, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fl\u00e9chon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367(13):1187\u20131197. https:\/\/doi.org\/10.1056\/NEJMoa1207506","journal-title":"N Engl J Med"},{"issue":"12","key":"309_CR37","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, Hussain M, Kelly WK, Liu G, Logothetis C, Nanus D, Stein MN, Rathkopf DE, Slovin SF, Ryan CJ, Sartor O, Small EJ, Smith MR, Sternberg CN, Taplin M-E, Wilding G, Nelson PS, Schwartz LH, Halabi S, Kantoff PW, Armstrong AJ (2016) Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials Working group 3. JCO 34(12):1402\u20131418. https:\/\/doi.org\/10.1200\/JCO.2015.64.2702","journal-title":"JCO"},{"key":"309_CR38","doi-asserted-by":"publisher","unstructured":"Soloway MS, Hardeman SW, Hickey D, Todd B, Soloway S, Raymond J, Moinuddin M (1988) Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61(1):195\u2013202. https:\/\/doi.org\/10.1002\/1097-0142(19880101)61:1%3C195::AID-CNCR2820610133%3E3.0.CO;2-Y","DOI":"10.1002\/1097-0142(19880101)61:1%3C195::AID-CNCR2820610133%3E3.0.CO;2-Y"},{"issue":"1","key":"309_CR39","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.eururo.2012.01.037","volume":"62","author":"D Ulmert","year":"2012","unstructured":"Ulmert D, Kaboteh R, Fox JJ, Savage C, Evans MJ, Lilja H, Abrahamsson P-A, Bj\u00f6rk T, Gerdtsson A, Bjartell A, Gjertsson P, H\u00f6glund P, Lomsky M, Ohlsson M, Richter J, Sadik M, Morris MJ, Scher HI, Sj\u00f6strand K, Yu A, Suurk\u00fcla M, Edenbrandt L, Larson SM (2012) A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the bone scan index. Eur Urology 62(1):78\u201384. https:\/\/doi.org\/10.1016\/j.eururo.2012.01.037","journal-title":"Eur Urology"},{"issue":"2","key":"309_CR40","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s12149-017-1224-x","volume":"32","author":"T Umeda","year":"2018","unstructured":"Umeda T, Koizumi M, Fukai S, Miyaji N, Motegi K, Nakazawa S, Takiguchi T (2018) Evaluation of bone metastatic burden by bone SPECT\/CT in metastatic prostate cancer patients: defining threshold value for total bone uptake and assessment in radium-223 treated patients. Ann Nucl Med 32(2):105\u2013113. https:\/\/doi.org\/10.1007\/s12149-017-1224-x","journal-title":"Ann Nucl Med"},{"issue":"1","key":"309_CR41","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1148\/radiol.2373041358","volume":"238","author":"D Utsunomiya","year":"2006","unstructured":"Utsunomiya D, Shiraishi S, Imuta M, Tomiguchi S, Kawanaka K, Morishita S, Awai K, Yamashita Y (2006) Added value of SPECT\/CT fusion in assessing suspected bone metastasis: comparison with scintigraphy alone and nonfused scintigraphy and CT. Radiology 238(1):264\u2013271. https:\/\/doi.org\/10.1148\/radiol.2373041358","journal-title":"Radiology"},{"issue":"2","key":"309_CR42","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/01.mlr.0000108746.69256.45","volume":"42","author":"KP Weinfurt","year":"2004","unstructured":"Weinfurt KP, Castel LD, Li Y, Timbie JW, Glendenning GA, Schulman KA (2004) Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Med Care 42(2):164\u2013175. https:\/\/doi.org\/10.1097\/01.mlr.0000108746.69256.45","journal-title":"Med Care"},{"issue":"4","key":"309_CR43","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1093\/annonc\/mdi122","volume":"16","author":"KP Weinfurt","year":"2005","unstructured":"Weinfurt KP, Li Y, Castel LD, Saad F, Timbie JW, Glendenning GA, Schulman KA (2005) The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 16(4):579\u2013584. https:\/\/doi.org\/10.1093\/annonc\/mdi122","journal-title":"Ann Oncol"},{"issue":"3","key":"309_CR44","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1007\/s12149-020-01568-2","volume":"35","author":"T Yamane","year":"2021","unstructured":"Yamane T, Fukushima K, Shirotake S, Nishimoto K, Okabe T, Oyama M, Seto A, Kuji I (2021) Test\u2013retest repeatability of quantitative bone SPECT\/CT. Ann Nucl Med 35(3):338\u2013346. https:\/\/doi.org\/10.1007\/s12149-020-01568-2","journal-title":"Ann Nucl Med"},{"issue":"7","key":"309_CR45","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1046\/j.1464-410X.2003.04169.x","volume":"91","author":"BK Yap","year":"2003","unstructured":"Yap BK, Choo R, Deboer G, Klotz L, Danjoux C, Morton G (2003) Are serial bone scans useful for the follow-up of clinically localized, low to intermediate grade prostate cancer managed with watchful observation alone? BJU Int 91(7):613\u2013617. https:\/\/doi.org\/10.1046\/j.1464-410X.2003.04169.x","journal-title":"BJU Int"}],"container-title":["EJNMMI Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41824-026-00309-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41824-026-00309-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41824-026-00309-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T22:09:13Z","timestamp":1783894153000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41824-026-00309-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["309"],"URL":"https:\/\/doi.org\/10.1186\/s41824-026-00309-4","relation":{},"ISSN":["3005-074X"],"issn-type":[{"value":"3005-074X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"31 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Institutional Review Board of Nippon Medical School (approval number: 30-12-1051). The requirement for informed consent was waived due to the retrospective nature of the study, in accordance with the institutional guidelines for retrospective observational research with an information disclosure procedure (opt-out).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"During the preparation of this work, the authors used Claude (Anthropic) for language editing and manuscript formatting. The authors reviewed and edited the content as needed and take full responsibility for the content of the publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of generative AI in scientific writing"}},{"value":"The authors declare that they have no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}